<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">MD-Onco</journal-id><journal-title-group><journal-title xml:lang="en">MD-Onco</journal-title><trans-title-group xml:lang="ru"><trans-title>MD-Onco</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2782-3202</issn><issn publication-format="electronic">2782-6171</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">87</article-id><article-id pub-id-type="doi">10.17650/2782-3202-2023-3-4-48-51</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND SELECTION OF TREATMENT TACTICS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕДКИЕ И СЛОЖНЫЕ КЛИНИЧЕСКИЕ СИТУАЦИИ: ДИАГНОСТИКА И ВЫБОР ТАКТИКИ ЛЕЧЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">A clinical case of cardiotoxicity caused by antitumor therapy with osimertinib and bevacizumab</article-title><trans-title-group xml:lang="ru"><trans-title>Клинический случай кардиотоксичности, вызванной противоопухолевой терапией осимертинибом и бевацизумабом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1564-424X</contrib-id><name-alternatives><name xml:lang="en"><surname>Zeynalova</surname><given-names>P. A.</given-names></name><name xml:lang="ru"><surname>Зейналова</surname><given-names>П. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p><p>Bld. 2, 8 Trubetskaya St., Moscow 119991</p></bio><bio xml:lang="ru"><p>кафедра онкологии</p><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p><p>119991 Москва, ул. Трубецкая, 8, стр. 2</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Albitskaya</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Альбицкая</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8581-1328</contrib-id><name-alternatives><name xml:lang="en"><surname>Chekini</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Чекини</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6395-5790</contrib-id><name-alternatives><name xml:lang="en"><surname>Akhobekov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Ахобеков</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Albert Amalievich Akhobekov</p><p>111 1st Uspenskoe Shosse, Lapino, Moscow region 143081</p></bio><bio xml:lang="ru"><p>Альберт Амалиевич Ахобеков</p><p>143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111</p></bio><email>alber-t7@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Clinical Hospital “Lapino” of the “Mother and Child” Group of companies</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Department of Oncology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-12-07" publication-format="electronic"><day>07</day><month>12</month><year>2023</year></pub-date><volume>3</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>48</fpage><lpage>51</lpage><history><date date-type="received" iso-8601-date="2023-12-07"><day>07</day><month>12</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-07"><day>07</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, АБВ-пресс</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://mdonco.abvpress.ru/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://mdonco.abvpress.ru/jour/article/view/87">https://mdonco.abvpress.ru/jour/article/view/87</self-uri><abstract xml:lang="en"><p>Oncological and cardiovascular diseases are the main causes of mortality worldwide. The rate of these pathologies tends to increase as the population ages. The implementation of highly effective therapeutic schemes has led to a significant increase in the survival rate of oncology patients over the last decades. In many cases, the mortality rate in oncology patients who underwent effective treatment is caused by cardiovascular events arising as a consequence of aggressive antitumor treatment or pre-existing chronic cardiovascular diseases. Among cardiovascular complications that developed both during active treatment of the malignant neoplasm and in the longer term, literature most often mentions cardiac insufficiency. We present a clinical case of successful diagnosis and treatment of severe heart insufficiency caused by antitumor therapy with bevacizumab and osimertinib in a patient with cancer of the upper lobe of the right lung and metastases into the brain.</p></abstract><trans-abstract xml:lang="ru"><p>Онкологические и сердечно-сосудистые заболевания являются основными причинами смертности, причем наблюдается тенденция к росту заболеваемости данными патологиями с учетом старения населения. Благодаря внедрению высокоэффективных схем противоопухолевой терапии выживаемость пациентов с онкологическими заболеваниями значительно выросла за последние десятилетия. Смертность у онкологических пациентов, получивших эффективное лечение, во многих случаях обусловлена сердечно-сосудистыми событиями, возникающими как следствие агрессивного противоопухолевого лечения или ранее существовавших хронических сердечно-сосудистых заболеваний. Из сердечно-сосудистых осложнений, развившихся как на фоне активного лечения злокачественного новообразования, так и в отдаленном периоде, в литературе чаще всего упоминается сердечная недостаточность. Приводим клинический случай успешной диагностики и лечения тяжелой сердечной недостаточности, вызванной противоопухолевой терапией бевацизумабом и осимертинибом, у пациентки с раком верхней доли правого легкого и метастазами в головной мозг.</p></trans-abstract><kwd-group xml:lang="en"><kwd>antitumor therapy</kwd><kwd>cardiotoxicity</kwd><kwd>cardio-oncology</kwd><kwd>cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>противоопухолевая терапия</kwd><kwd>кардиотоксичность</kwd><kwd>кардиоонкология</kwd><kwd>рак</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Soria J.C., Ohe Y., Vansteenkiste J. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113–25. DOI: 10.1056/NEJMoa1713137</mixed-citation><mixed-citation xml:lang="ru">Soria J.C., Ohe Y., Vansteenkiste J. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113–25. DOI: 10.1056/NEJMoa1713137</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Ewer M.S., Tekumalla S.H., Walding A., Atuah K.N. Cardiac safety of osimertinib: a review of data J Clin Oncol 2021;39(4):328–37. DOI: 10.1200/JCO.20.01171</mixed-citation><mixed-citation xml:lang="ru">Ewer M.S., Tekumalla S.H., Walding A., Atuah K.N. Cardiac safety of osimertinib: a review of data J Clin Oncol 2021;39(4):328–37. DOI: 10.1200/JCO.20.01171</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328–35. DOI: 10.1016/j.bbrc.2005.05.132</mixed-citation><mixed-citation xml:lang="ru">Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333(2):328–35. DOI: 10.1016/j.bbrc.2005.05.132</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Economopoulou P., Kotsakis A., Kapiris I., Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133–43. DOI: 10.2147/CMAR.S77400</mixed-citation><mixed-citation xml:lang="ru">Economopoulou P., Kotsakis A., Kapiris I., Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133–43. DOI: 10.2147/CMAR.S77400</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244</mixed-citation><mixed-citation xml:lang="ru">Lyon A.R., López-Fernández T., Couch L.S. et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244</mixed-citation></citation-alternatives></ref></ref-list></back></article>
